Literature DB >> 33515024

HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues.

Jiao Gong1, Rong Li2, Yaqiong Chen1, Zhenjian Zhuo3, Shuru Chen4, Jing Cao4, Qi Zhang5, Yutian Chong4, Bo Hu1.   

Abstract

The prognostic role of adjacent nontumor tissue in hepatocellular carcinoma (HCC) patients is still not clear. The activity changes of immunologic and hallmark gene sets in adjacent nontumor tissues may substantially impact on prognosis by affecting proliferation of liver cells and colonization of circulating tumor cells after HCC treatment measures such as hepatectomy. We aimed to identify HCC subtypes and prognostic gene sets based on the activity changes of gene sets in tumor and nontumor tissues, to improve patient outcomes. We comprehensively revealed the activity changes of immunologic and hallmark gene sets in HCC and nontumor samples by gene set variation analysis (GSVA), and identified three clinically relevant subtypes of HCC by nonnegative matrix factorization method (NMF). Patients with subtype 1 had good overall survival, whereas those with subtype 2 and subtype 3 had poor prognosis. Patients with subtype 1 in the validation group also tended to live longer. We also identified three prognostic gene sets in tumor and four prognostic gene sets in nontumor by least absolute shrinkage and selection operator method (LASSO). Interestingly, functional enrichment analysis revealed that in nontumor tissues, genes from four gene sets correlated with immune reaction, cell adhesion, whereas in tumor tissue, genes from three gene sets closely correlated with cell cycle. Our results offer new insights on accurately evaluating prognosis-the important role of gene sets in both tumor and adjacent nontumor tissues, suggesting that when selecting for HCC treatment modality, changes in tumor and nontumor tissues should also be considered, especially after hepatectomy.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bioinformatic analysis; hepatocellular carcinoma; immunologic and hallmark gene sets; prognosis

Year:  2021        PMID: 33515024     DOI: 10.1093/bib/bbaa427

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  10 in total

1.  Glioma Subtypes Based on the Activity Changes of Immunologic and Hallmark Gene Sets in Cancer.

Authors:  Sihan Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-13       Impact factor: 6.055

2.  Identification of EMT-Related Genes and Prognostic Signature With Significant Implications on Biological Properties and Oncology Treatment of Lower Grade Gliomas.

Authors:  Jiasheng Wu; Jinru He; Jiheng Zhang; Hang Ji; Nan Wang; Shuai Ma; Xiuwei Yan; Xin Gao; Jianyang Du; Zhihui Liu; Shaoshan Hu
Journal:  Front Cell Dev Biol       Date:  2022-05-17

3.  Identification of Novel Subtypes in Lung Adenocarcinoma: Evidence from Gene Set Variation Analysis in Tumor and Adjacent Nontumor Samples.

Authors:  Feng Li; Bin Wan; Xuan He; Xiaoqing Li
Journal:  Dis Markers       Date:  2022-01-19       Impact factor: 3.434

4.  Head and Neck Squamous Cell Carcinoma Subtypes Based on Immunologic and Hallmark Gene Sets in Tumor and Non-tumor Tissues.

Authors:  Ji Yin; Xinling He; Hui Xia; Lu He; Daiying Li; Lanxin Hu; Sihan Zheng; Yanlin Huang; Sen Li; Wenjian Hu
Journal:  Front Surg       Date:  2022-02-03

5.  An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer.

Authors:  Qing Liu; Yunchao Wang; Huayu Gao; Fahai Sun; Xuan Wang; Huawei Zhang; Jianning Wang
Journal:  Front Genet       Date:  2022-03-29       Impact factor: 4.599

6.  Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates.

Authors:  Chengbin Guo; Yuqin Tang; Zhao Yang; Gen Li; Yongqiang Zhang
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

7.  Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.

Authors:  Hongjun Xie; Muqi Shi; Yifei Liu; Changhong Cheng; Lining Song; Zihan Ding; Huanzhi Jin; Xiaohong Cui; Yan Wang; Dengfu Yao; Peng Wang; Min Yao; Haijian Zhang
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

8.  A Novel circRNA hsa_circRNA_002178 as a Diagnostic Marker in Hepatocellular Carcinoma Enhances Cell Proliferation, Invasion, and Tumor Growth by Stabilizing SRSF1 Expression.

Authors:  Jing Li; Ting Han; Zhenzhen Li; Hongmei Han; Yingchun Yin; Baohua Zhang; Hengming Zhang; Luan Li
Journal:  J Oncol       Date:  2022-08-27       Impact factor: 4.501

9.  Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.

Authors:  Zhongzheng Sun; Yongquan Zhao; Yan Wei; Xuan Ding; Chenyang Tan; Chengwei Wang
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

10.  Gastric Cancer Subtypes in Tumour and Nontumour Tissues by Immunologic and Hallmark Gene Sets.

Authors:  Xia Zheng; Yanzhong Wang; Yirui Chen
Journal:  J Oncol       Date:  2022-08-27       Impact factor: 4.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.